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Abstract: Rilpivirine is associated with a good efficacy and safety profile. However, data from 
real-life settings are scarce. 
Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral 
therapy in a prospective, observational, multicenter study. 
Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5 years, 
mean CD4 600 ± 327 cell/µL, mean HIV-RNA 3.80 ± 1.15 log10 cp/mL. After a median follow 
up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events 
(16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological 
failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at 
week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p= 0.007). In patients 
switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides 
at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio 
showed a statistically significant decrease at week 24 (p= 0.0008) and 72 (p= 0.04). A significant 
increase at week 24 and 48 in AST and ALT values was observed. Patients switching from 
TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 
48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 
48 (p= 0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were 
associated with RPV discontinuation. 
Conclusion: In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with 
improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, 
liver and kidney parameters should be monitored.
Keywords: HIV-1, combination antiretroviral therapy, NNRTI, cohort study, naive, experienced 
patients
Introduction
Rilpivirine (RPV) is a non-nucleoside reverse-transcriptase inhibitor (NNRTI) indi-
cated at first in naive patients with an HIV-RNA of < 100,000 copies/mL and CD4 
count > 200 cells/mm3. Since 2013, it has also been used for treatment-experienced 
patients with virological suppression and without NNRTI-resistance mutations. RPV 
is available as a single drug (RPV, 25 mg tablet) or co-formulated with tenofovir and 
emtricitabine (TDF/FTC/RPV, 245/200/25 mg tablet) or with tenofovir alafenamide 
and emtricitabine (TAF/FTC/RPV, 25/200/25 mg tablet) in a single tablet regimen.1,2 
In the current European AIDS Clinical Society guidelines, RPV remains a recom-
mended regimen for antiretroviral-naive HIV-infected patients with an HIV-RNA 
of < 100,000 copies/mL and CD4 count > 200 cells/mm3.3 Furthermore, in the latest 
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Department of Health and Human Services guidelines, RPV 
is recommended as initial regimen in certain clinical situa-
tions, underlining that a RPV-based regimen is effective and 
tolerable, but has some disadvantages when compared with 
integrase inhibitor-based regimens, which are actually the 
recommended initial regimens for most people with HIV.4
RPV is a substrate of hepatic cytochrome P450 3A4, 
and therefore, drugs that induce or inhibit the action of 
this isoenzyme may alter serum RPV levels. Rifamycins, 
anticonvulsivants, and St. John’s wort may decrease RPV 
concentrations and should be avoided.1,2 Macrolides, azole, 
and protease inhibitors (PIs) may increase RPV levels. Some 
pharmacodynamics interactions exist: since an acidic gas-
tric  environment is necessary for absorption, proton pump 
inhibitors should not be given to patients taking RPV.1,2 To 
guarantee sufficient absorption, RPV should be taken with 
food (a meal of at least 500 kcal is required).5
As with other NNRTIs, drug interactions and a low resis-
tance barrier have to be considered.
Data from clinical studies have suggested that TDF/FTC/
RPV is associated with a good safety profile, especially with 
regard to lipid metabolism. An improvement of lipid param-
eters was observed with RPV compared with efavirenz (EFV) 
or PI, with a decrease in total and low-density lipoprotein 
cholesterol (LDL) and triglycerides.6–8
Headache, insomnia, and central nervous system (CNS) 
symptoms (depressive and suicidal disorders) occur less 
frequently than with EFV.6,7 A mild rash can occur in the 
first week and treatment is usually continued. Few data are 
available on efficacy and safety of RPV-based treatment in 
clinical practice from observational cohorts.
Our aim is to describe the durability, safety, and efficacy 
of a combination antiretroviral therapy (cART) regimen 
including RPV in real life. Specifically, we evaluated the 
modification of estimated glomerular filtration rate (eGFR) 
and liver and lipid profile in naive and experienced patients, 
most of whom switched to RPV from a PI or a TDF/FTC/
EFV-based regimen.
Methods
The SCOLTA Project is a prospective, observational, multi-
center study created to assess the incidence of adverse events 
(AEs) in patients receiving new antiretroviral drugs in clinical 
practice. It is an online pharmacovigilance program involving 
22 Italian Infectious Disease Departments. The approving coor-
dinating center is ASST Fatebenefratelli Sacco-Milano, Italy.
The Project has an Internet site (http://www.cisai.info) 
where grade 3 and 4 AEs are recorded (http://rcc.tech-res-
intl.com/tox_tables.htm). The SCOLTA Project currently 
includes 3 cohorts: RPV, elvitegravir/cobicistat/TDF/FTC, 
and dolutegravir. Patients who start taking a cohort drug are 
consecutively enrolled in that cohort and asked to give writ-
ten informed consent. To date, no one has refused. As this is 
an observational study, the choice of therapy is entirely up to 
the individual physicians and patients in each center. Patients 
are followed up according to the standards of each center. 
The study has been approved by the ethics committee of the 
coordinating and the participating centers. At baseline, clini-
cal characteristics, laboratory variables, cART history, and 
comorbidities are recorded. Data regarding enrolled patients 
are registered at 6-month intervals, and AEs, therapy inter-
ruptions, and their causes are notified when they are clinically 
observed. AEs are described according to the Division of 
AIDS table.9 Complete data collection and follow-up proce-
dures for the cohorts are described elsewhere.10,11 Virological 
failure (VF) or discontinuation was defined by the clinicians 
according to current guidelines.3,4 eGFR was calculated using 
the Modification of Diet in Renal Diseases formula.
Statistical analysis
Data were described using mean (± SD) for normally dis-
tributed continuous variables, median (interquartile range, 
IQR) for not normally distributed continuous variables, 
and frequency (%) for categorical and ordinal variables. At 
univariate analyses, differences between groups (naive and 
experienced) were evaluated by means of analysis of variance, 
Mann–Whitney U-test, chi-square test, and Cochrane–Man-
tel–Hanszel test. Changes from baseline were analyzed using 
Student’s t-test for paired data.
Treatment interruption was evaluated using the Kaplan–
Meier curve; variables were compared using the log-rank test. 
To simultaneously account for several potential confounders, 
we determined the hazard ratio (HR) and corresponding 95% 
CI of discontinued RPV by the Cox proportional hazards 
models, including variables associated at univariate analysis 
in the model.
Ethical approval
The SCOLTA Project has been approved by the ethical com-
mittees of the coordinating and the participating centers. 
All patients enrolled in the study gave written informed 
consent.
Results
Enrolment started in January 2013 and is ongoing. A total 
of 499 HIV-infected patients were included in the study, 
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360 (72.1%) of whom were males and 456 (91.4%) were 
Caucasian. In 390 (78.2%) patients, the risk factor for HIV 
acquisition was sexual intercourse. Mean age at enrolment 
was 43.4±10.5 years. Centers for Disease Control and Pre-
vention (CDC) stage was A in 310 (62.1%) patients, mean 
CD4+  cell count was 600±327 cell/µL, and mean HIV-RNA 
when detectable was 3.80±1.15 log10 cp/mL; 138 (27.7%) were 
naive and 361 (72.3%) were experienced. Median duration of 
previous regimens in experienced patients was 6.4 years (IQR: 
2.9–13.1 years). Ten (2.0%) subjects started therapy with viral 
load (VL) > 100,000 copies/mL, 5 of whom were naive and 5 
experienced (1.4% vs 3.6%, p= 0.11). Ninety-seven (19.5%) 
patients were hepatitis C virus antibody (HCV-Ab) positive: 
12 (8.8%) were naive and 85 (23.6%) were treatment expe-
rienced. The most common treatment was TDF/FTC/RPV 
in 455 patients (91.2%) followed by abacavir/lamivudine +  
RPV in 21 patients (4.2%). Demographic and clinical charac-
teristics of patients are summarized in Table 1. As expected, 
naive and cART-experienced patients were significantly dif-
ferent with regard to age, HIV transmission category, CDC 
stage, and CD4+  count, as well as HCV coinfection, blood 
lipids, including total cholesterol/high-density lipoprotein 
cholesterol (TC/HDL) ratio, transaminase levels, and eGFR.
The proportion of naive patients reaching virologic suc-
cess (HIV-RNA load < 50 cp/mL) was 88.7%, 89.8%, and 
93.2% at week 24, 48, and 72, respectively, whereas the 
Table 1 Comparison of naive and experienced patients starting a rilpivirine-based combination antiretroviral therapy
Naive (N=138, 27.7%) Experienced (N=361, 72.3%) p-value
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Undetectable HIV viral load N (%) − − 70 19.4 −
Lipodystrophy N (%) 5 3.6 55 15.2 0.0004
HCV antibody positive (2 missing) N (%) 12 8.8 85 23.6 0.0002
HCV-RNA positive (n= 87) N (%) 2 18.2 49 64.5 0.006

















Total cholesterol (md/dL)* 165.0 35.4 188.4 42.1 < 0.0001
HDL-C (md/dL)* 40.8 13.2 48.5 16.7 < 0.0001
Triglycerides (md/dL)** 98.5 68.5–133.5 120 85–168 < 0.0001
Blood glucose (md/dL)* 87.8 20.4 91.6 21.2 0.07
AST (U/L)** 23 17–29 24 19–32 0.03
ALT (mg/dL)** 24 18–31 28 21–42 0.0001
eGFR (mg/dL)** 104 90–115 93 80–108 < 0.0001
Note: Data are expressed and mean ± standard deviation (SD)* or median and interquartile range (IQR)**.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; EFV, efavirenz; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; HCV, hepatitis C 
virus; HDL-C, high-density lipoprotein cholesterol; IVDU, intravenous drug user; PI, protease inhibitor; RPV, rilpivirine; TDF, tenofovir.





rank p= 0.0003), and among experienced patients more fre-
quently switching from PI than from TDF/FTC/EFV (27.0% 
vs 15.4%, log rank p= 0.02).
With the Cox model, including variables that were statisti-
cally significant at univariate analyses, we confirmed the role 
of being in CDC stage C (HR for treatment interruption 1.76, 
95% CI: 1.04–2.98, reference category A+ B) and experienced 
(HR: 2.47, 95% CI: 1.27–4.81, reference category naive). 
Limiting the analysis to experienced patients, a switch from 
PI (HR: 2.51, 95% CI: 1.17–5.38) but not from TDF/FTC/
EFV, compared with other previous regimens (mainly NRTI 
based and Integrase Inhibitor based), represented a risk factor 
for RPV discontinuation. When we compared switching from 
PI with switching from TDF/FTC/EFV, we found that the risk 
was still higher (HR: 1.89, 95% CI: 1.08–3.30).
Follow-up evaluation
Treatment naive
Among naive patients with available follow-up data at 
week 24, 48, and 72, we found a significant reduction in 
eGFR at all follow-up times (−8.9±15.6 mL/min/1.73 m2, 
p< 0.0001; −12.0±18.8 mL/min/1.73 m2, p< 0.0001; and 
9.1±17.3 mL/min/1.73 m2, p< 0.0001, respectively) as shown in 
Figure 1. Regarding lipid profile, we did not observe significant 
changes in total cholesterol, HDL-cholesterol, and triglycer-
ides during follow-up. TC/HDL ratio showed a decrease that 
reached a statistical significance at week 48 (−0.41; p= 0.0007). 
Furthermore, blood glucose, aspartate alanine transaminase 
(ALT), and alanine transaminase (ALT)levels did not show 
significant modifications when compared with baseline values.
Treatment experienced
Our cohort also included 361 (72.3%) experienced patients: 
162 (44.9%) switched from boosted PI-based regimen 
Table 2 Comparison of treatment interruptions in naive and 
experienced patients receiving a rilpivirine-based cART
Naive Experienced p-value











































Abbreviation: cART, combination antiretroviral therapy.
corresponding figures in treatment-experienced patients were 
89.3%, 91.5%, and 96.2%, respectively. Patients switching 
from TDF/FTC/EFV maintained viral suppression at 93.7%, 
96%, and 94.6% at week 24, 48, and 72, respectively, whereas 
in those switching from a PI, the percentages were 86.8%, 
87.8%, and 97.7%, respectively.
After a median follow-up of 16 months (IQR: 
9–21 months), 81 (16.2%) patients discontinued RPV treat-
ment: 11 in the naive group and 70 in the experienced one.
Discontinuations of therapy occurred for the following 
reasons: 36 (7.2%) AEs, 17 (3.4%) lost to follow-up, 4 (0.8%) 
therapy simplification, 7 (1.4%) patient’s decision/low adher-
ence, and 7 (1.4%) other motivations such as drug–drug inter-
actions and pregnancy. Eight (1.6%) VFs occurred: 1 (0.7%) 
in a naive patient and 7 (1.9%) in experienced ones. Among 
them, 1 subject had initiated treatment with VL > 100,000 
copies/mL, 1 who switched from a PI had a VL= 59 copies/
mL at enrolment, and the remaining 5 had a suppressed VL 
(3 were previously on PI and 2 on TDF/FTC/EFV). Two 
patients were also co-infected with HCV.
Two (0.4%) experienced patients died, 1 from myocardial 
infarction and 1 from heart valve rupture. Among AE-related 
interruptions, 16 were ≥3 grade reactions. In particular, we 
registered 1 acute renal failure, 1 grade 4 ALT elevation, 1 
hepatotoxicity, 4 gastrointestinal toxicity, 2 rashes, 3 arthral-
gia, and 1 tachypnea/asthenia. Five patients reported grade 
3–4 symptoms related to CNS toxicity (insomnia, dizziness, 
depression, headache, and 1 unspecified) and a psychiatric 
event was also described. In 4 cases, interruption was due 
to more than 1 AE.
Among patients who interrupted RPV because of grade 
1–2 AEs, we found 2 liver events (transaminase increase and 
unspecified hepatitis), 3 rashes, 3 gastrointestinal toxicities, 
3 arthralgia, 1 asthenia, 3 CNS events (dizziness, psychomo-
tor agitation, and 1 unspecified), 4 renal impairment, and 1 
worsening lipoaccumulation.
The median time to AE-related treatment interruption was 
7.5 (IQR: 2.0–14.5) in experienced and 12 (IQR: 4.5–18.5) 
months in naive patients. Dermatologic, gastrointestinal 
and, to a lesser extent, CNS AEs causing discontinuation 
occurred early (< 6 months), whereas all renal AEs occurred 
after 12 months.
Reasons for interruption are shown in Table 2.
At univariate analysis, subjects who withdrew from treat-
ment were more frequently females than males (23.7% vs 
13.3%, log-rank p= 0.02), over 45 years old (20.1% vs 12.7%, 
log rank p= 0.01), in stage C rather than A or B (25.0% vs 
14.7%, log rank p= 0.003), experienced (19.4% vs 8.0%, log 
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(43.8% atazanavir, 32.1% darunavir, 14.2% lopinavir, and 
9.9% other PIs), 135 (37.4%) from a regimen based on TDF/
FTC/EFV, and 64 (17.7%) switched from other regimens (13 
integrase inhibitor-based regimens and 51 others). Changes 
in eGFR, lipid profile, blood glucose, AST, and ALT are 
shown in Figure 1.
The patients who switched from a PI-based regimen 
showed a slight but statistically significant decrease in TC 
(−15.0±35.6 mg/dL, p< 0.0001 at 24 weeks; and −9.9±35.2 
mg/dL at 48 weeks, p= 0.007) and triglycerides levels at 
week 24, 48, and 72 (−27±105 mg/dL, p= 0.004; −34±86 mg/
dL, p= 0.0002; −49.9±89.5 mg/dL, p= 0.0003, respectively), 
and a slight and nonsignificant (both from a statistical and 
clinical point of view) reduction change in HDL cholesterol 
(Figure 1). A significant reduction in eGFR was observed at 
week 48 (−4.4±18.3 mL/min/1.73 m2, p= 0.02) and at week 
72 (−7.3±17.3 mL/min/1.73 m2, p= 0.004). TC/HDL ratio 
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Figure 1 Changes from baseline to 24, 48, and 72 weeks in eGFR (A), lipid profile (B–D), and AST and ALT (E, F) in patients switching to rilpivirine from previous treatment.
Abbreviations: ALT,  alanine transaminase; AST, aspartate transaminase; EFV, efavirenz; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; HDL, High-density 
lipoprotein; PI, protease inhibitor; TDF, tenofovir. 





(−0.29; p= 0.0008) and 72 (−0.35; p= 0.04), whereas at week 
48, it showed a trend toward significance (−0.20; p= 0.05), 
as shown in  Figure 2. On the contrary, we observed a slight 
but significant increase in AST (6 ± 15 IU/mL, p< 0.0001 
and 10±31 UI/mL, p= 0.002) and ALT values (11±24 IU/mL, 
p< 0.0001 and 15±66 IU/mL, p= 0.02) at week 24 and 48, but 
not at week 72, as shown in Figure 1.
The patients switching from a TDF/FTC/EFV regimen 
showed a statistically significant reduction in eGFR at all 
follow-up times (−7.5±16.1 mL/min/1.73 m2, p< 0.0001, 
−8.0±19.7 mL/min/1.73 m2, p= 0.0004 and −10.2±16.7 
mL/min/1.73 m2, p= 0.0004). A statistically significant 
reduction was observed at week 24 and 48 in total choles-
terol (−16.7±27.5 mg/dL, p< 0.0001, −23.5±30.3 mg/dL, 
p< 0.0001) and triglycerides (−17±65 mg/dL, p= 0.006, 
and −24±66 mg/dL, p= 0.001). HDL-cholesterol showed a 
significant reduction at week 24 and 48 (−2.8±8.4 mg/dL, 
p= 0.0004 and −3.2±9.1 mg/dL, p= 0.002, respectively), but 
not at week 72. TC/HDL ratio showed a decrease at week 
24 that became significant at week 48 (−0.26±0.88 mg/dL; 
p= 0.01), as shown in Figure 2. AST and ALT levels did not 
vary markedly during the observation period (Figure 1).
Discussion
In this study, we described the efficacy, safety, and tolerabil-
ity of a cART regimen, including RPV in 499 HIV-infected 
patients. In this real-life setting, after a median follow-up of 
16 months, 81 (16.2%) patients had discontinued RPV treat-
ment, mainly because of AEs, the interruptions of treatment 
with RPV occurs mainly in experienced patients rather than 
in naive subjects (8.9% vs 2.9%).
In the study period, we observed VF in 8 patients (1.6%), 
1 of whom was naive (0.7%) and 7 (1.9%) were treatment 
experienced.
Available data on RPV efficacy are mostly derived from 
clinical trials in both naive and experienced patients.
In naive patients, RPV has been comparatively tested with 
EFV in 3 large trials. In 2 of these (ECHO and THRIVE), 
both Phase III, in 1368 patients, a comparable effect with bet-
ter tolerability was observed at 48–96 weeks,6,7 and VF rates 
were 10% vs 6%, respectively, whereas in the sub-analysis 
by baseline VL (≤100,000 copies/mL), VF reached the same 
proportion in the 2 arms (5%).12 In the third trial (STaR), the 
2 single-table regimens TDF/FTC/RPV and TDF/FTC/EFV 
were compared. This randomized, open-label trial included 
786 patients and demonstrated non-inferior efficacy, including 
superiority in patients with HIV-RNA ≤100,000 cp/mL.12 In the 
overall study population, after 48 weeks, 86% of TDF/FTC/
RPV vs 82% of TDF/FTC/EFV patients achieved undetectable 
VL  and VF in the overall population and in the population with 
HIV-RNA < 100000. In the overall population, VF rate was 8.1% 
for TDF/FTC/RPV vs 5.6% for TDF/FTC/EFV, whereas the 
corresponding figure in patients with HIV-RNA ≤100,000 cop-
ies/mL was 5% and 3.2%, respectively.13 The incidence of VF 
was higher for RPV, but was observed mostly in patients with 
baseline HIV-RNA> 100,000 copies/mL. Improved tolerability 
was shown in patients receiving TDF/FTC/RPV compared with 
TDF/FTC/EFV.13
In this study, the proportion of naive patients reaching 
virologic success was similar to that observed in the random-
ized trials described above, thus confirming the efficacy of 
RPV in clinical practice.6,7,12,13
In an observational study, after a median of 2.6 months, VF 
occurred in 3 patients (1%) switched from a PI-based regimen.14
In the SPIRIT trial, 476 treatment-experienced patients 
with viral suppression were randomized to remain on their 
PI-based regimen or switch to RPV, and VF was observed 
in 2.5% of patients.8
In this study, the proportion of VF in patients with 
HIV≤100,000 copies/mL resulted lower than that of clinical 
trials and similar to that of other observational studies with 
shorter follow-up.
We observed a 7.2% rate of AE-related discontinuation 
that included 8 (1.6%) CNS events.
In the STaR trial, RPV was well tolerated, although CNS 































Figure 2 Changes in total cholesterol/HDL ratio from baseline to 24, 48, and 72 
weeks. 
Abbreviations: EFV, efavirenz; FTC, emtricitabine; HDL, high-density lipoprotein; 
PI, protease inhibitor; TDF, tenofovir.
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with EFV. Fewer AE-related discontinuations were observed 
(2.5% vs 8.7%, respectively), as well as fewer serious AEs 
(7.4% vs 13.8%), in the RPV than EFV arm.13 In the SPIRIT 
study, only 7 participants, out of 297 (2.4%) in the RPV 
arm, discontinued treatment because of AE, thus confirming 
that the switch was safe and better tolerated compared with 
continuing PI treatment.8
In the study by Gianotti et al,14 the most frequent causes 
of AE-related interruptions were gastrointestinal toxicity (6 
cases, all of dyspepsia/epigastric pain), followed by a reduc-
tion in eGFR values (5 cases) and neurological toxicity (4 
cases; headache in 2, dizziness in 1, and depressed mood in 1).
In an Italian multicenter study including 508 patients 
on a cART simplified to an single tablet regimen including 
RPV, in a median follow-up of 196 days, 31 (6.1%) patients 
discontinued the regimen. VF occurred in 8 (1.6%) patients.15
In this study, interruptions caused by AEs were higher 
than the above-mentioned clinical trials (7.2% vs 2.5% 
in the STaR and 2.4% in the SPIRIT trial),13,14,8 Different 
rates of interruptions were also shown in comparison with 
the previously reported observational studies, even though 
it should be noted that our patients were followed up for a 
significantly longer period.
With regard to durability, patients in CDC stage C and 
treatment experienced were independently associated with 
treatment interruptions in Cox model. Limiting the analysis 
to experienced patients, switching from PI, but not from 
TDF/FTC/EFV, comparing with other previous regimens 
represented a risk factor for RPV discontinuation. When we 
compared switching from PI to switching from TDF/FTC/
EFV, we found that the risk was still higher.
Taken together, these results seem to suggest that patients 
in a more advanced stage and those with a longer treatment 
history are at higher risk of stopping RPV from any cause, and 
therefore, candidates should be carefully selected. Further-
more, patients switching from PI are at an even higher risk, 
probably due to a combination of patients’ characteristics, 
including more advanced disease.
We also further investigated the modification of eGFR 
and liver and lipid profile in naive and experienced patients 
during follow-up.
In the naive population, starting a regimen with RPV 
was not associated with a significant change in lipid profile, 
since we found an immediate decrease of total cholesterol 
that was not confirmed during follow-up and an elevation of 
triglycerides, even if not statistically significant. This study 
confirmed the minimal impact on fasting TC, HDL, and 
triglycerides in the naive population as previously seen in 
the literature.13
With experienced patients, we found that a switch to a RPV-
based regimen was associated with an improvement in total 
cholesterol and triglycerides levels, regardless of whether the 
patients were switched from a PI- or NNRTI-based regimen.
A beneficial effect on lipid profile in experienced patients 
has already been reported in the SPIRIT trial,14 and in some 
observational studies, showing the decrease in TC, LDL, 
and triglycerides after switching from any regimen, although 
more marked when from boosted PI.8,14,15
To better clarify the clinical impact of the lipid modifi-
cation related to RPV therapy in this study, we investigated 
the TC/HDL ratio, known as a strong predictor of coronary 
heart disease.16
Different from what seen in other observational study,14 
we found the reduction of TC/HDL ratio statistically sig-
nificant during the follow-up period at week 24 and 72 in 
patients switching from PI and at week 48 in both naive and 
those switching from TDF/FTC/EFV.
Modification of the cART regimen could be an important 
strategy to reduce cardiovascular risk, together with lifestyle 
modification, smoking cessation, and other interventions 
on modifiable risk factors. Our data show that, in a real-life 
scenario, RPV-based regimens, mostly co-formulated as 
TDF/FTC/RPV, are associated with a lipid-friendly profile. 
Of note, switching to RPV seems beneficial both in patients 
previously receiving PI or TDF/FTC/EFV and in naives and 
is associated with a significant reduction of TC/HDL ratio in a 
longer follow-up with respect to other previous studies. Taken 
together, these results suggest that RPV could contribute to 
reduced cardiovascular risk over time.
The observed reduction in eGFR was expected, since RPV 
has been known to cause the inhibition of the organic cation 
transporter, the active transporter of creatinine in the proximal 
renal tubule.17 It has been shown that it occurs in the first few 
weeks of treatment and does not usually worsen thereafter. 
However, changes in eGFR do not necessarily reflect changes 
in true GFR, as calculated by iohexol clearance.18,19 In our 
sample, this reduction was slight but statistically significant, 
both in patients starting first-line therapy with a RPV-based 
regimen and in cART-experienced ones in line with previous 
reports of clinical trials.8
The observational design of this study does not allow us 
to conclude that these changes were due to the introduction 
of TDF or RPV or both. However, the described change in 
eGFR did not seem to have effects on clinical management. 
In fact, in only 5 cases, the changes in eGFR were considered 
clinically relevant and led to treatment interruptions.
Regarding liver safety, we found a statistically signifi-
cant increase in AST and ALT values, at all follow-up times 





in patients who switched from a PI-based regimen, whereas 
no significant changes were observed in those switching 
from TDF/FTC/EFV and in naives. Our data are, in part, 
similar to those described in the switch study by Gianotti 
et al14 in which a statistically significant increase of AST, 
but not of ALT, was found. The ALT increase, in our cases, 
could possibly be related to the higher HCV co-infection 
rate in our experienced patients (23.6% vs 15%) and also 
to the longer follow-up duration. Although we observed 
only 4 discontinuations due to hepatic toxicity, our results 
highlight the need for a monitoring of AST and ALT values 
during follow-up.
This study has some limitations that should be acknowl-
edged. First, this is a cohort study in an observational setting, 
so confounding could not be completely ruled out. Second, 
the reasons for switching to a RPV-containing regimen or 
starting RPV in naive patients were not available. Third, the 
causes of discontinuation are those reported by the physician 
and therefore subjective by definition. Clinicians’ strategies 
may also slightly vary in different clinical centers.
Nevertheless, we believe that our results could provide 
clinicians with some useful information on the “real-world” 
experience with RPV-containing regimens.
In conclusion, the results of this study confirm the effi-
cacy, safety, and tolerability in clinical practice of a regimen 
containing RPV for first-line therapy or for a switch in pre-
treated HIV-1-infected patients. In particular, we confirm the 
positive impact of a regimen including RPV on lipid profile 
as seen in clinical trials and observational studies. Although 
rare, hepatic events can occur, and this suggests a monitoring 
of liver toxicity during follow-up.
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